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AbstrAct
Objectives Assess the association between marine 
omega-3 polyunsaturated fatty acid (n-3 PUFA) intake 
from supplements, mainly cod liver oil, and coronary 
heart disease (CHD) mortality.
Design Prospective cohort study, with three exposure 
measurements over 22 years.
setting Norfolk-based European Prospective Investigation 
into Cancer (EPIC-Norfolk, UK).
Participants 22 035 men and women from the general 
population, 39–79 years at recruitment.
Exposure Supplement use was assessed in three 
questionnaires (1993–1998; 2002–2004; 2004–2011). 
Participants were grouped into non-supplement users 
(NSU), n-3 PUFA supplement users (SU+n3) and non–n-3 
PUFA supplement users (SU-n3). Cox regression adjusted 
for time-point specific variables: age, smoking, prevalent 
illnesses, body mass index, alcohol consumption, 
physical activity and season and baseline assessments 
of sex, social class, education and dietary intake (7-day 
diet diary).
Primary and secondary outcome measures During 
a median of 19-year follow-up, 1562 CHD deaths were 
registered for 22 035 included participants.
results Baseline supplement use was not associated 
with CHD mortality, but baseline food and supplement 
intake of n-3 PUFA was inversely associated with CHD 
mortality after adjustment for fish consumption. Using 
time-varying covariate analysis, significant associations 
were observed for SU+n3 (HR: 0.74, 95% CI 0.66 to 
0.84), but not for SU-n3 versus NSU. In further analyses, 
the association for SU+n3 persisted in those who did not 
take other supplements (HR: 0.83, 95% CI 0.71 to 0.97). 
Those who became SU+n3 over time or were consistent 
SU+n3 versus consistent NSU had a lower hazard of 
CHD mortality; no association with CHD was observed 
in those who stopped using n-3 PUFA-containing 
supplements.
conclusions Recent use of n-3 PUFA supplements 
was associated with a lower hazard of CHD mortality 
in this general population with low fish consumption. 
Residual confounding cannot be excluded, but the 
findings observed may be explained by postulated 
biological mechanisms and the results were specific to 
SU+n3.
IntrODuctIOn
The traditionally high omega-3 polyunsat-
urated fatty acid (n-3 PUFA) intake among 
the Inuit has been associated with a lower 
risk of ischaemic heart disease mortality in 
this population.1 Research leading on from 
this observed that in a Dutch cohort, where 
average fish consumption was 20 g/day, higher 
fish consumption was associated with lower 
relative risk of coronary heart disease (CHD) 
mortality between 1960–1980.2 A recent review 
of prospective cohort studies has observed a 
16% (95% CI 5% to 25%) lower risk of CHD 
mortality in those consuming one portion of 
fish per week compared with lower frequency 
of consumption; however, null findings among 
included studies were equally observed.3 The 
association between fish intake and CHD 
has been attributed to n-3 PUFA, which are 
mainly derived from oily fish. According to 
the National Diet and Nutrition Survey in 
2000/2001, less than 50% of the UK popula-
tion consumed oily fish once a week4; however, 
dietary supplements may provide 50% of the 
n-3 PUFA intake.5
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Research
strengths and limitations of this study
 ► The use of dietary supplements was measured three 
times over the course of 22 years.
 ► The repeated measures enabled to study change in 
supplement use in relation to hard endpoints.
 ► The cohort was population-based as opposed to 
trials on omega-3 supplement use which have been 
in high-risk populations.
 ► Total omega-3 intake from both food (mainly 
fish sources) and supplement sources could be 
quantified; however, only for the baseline measure.
 ► Estimates were adjusted for sociodemographic and 
other behavioural risk factors, although residual 
confounding cannot be excluded.
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N-3 PUFA at pharmaceutical doses reduce plasma 
triglycerides and possibly thrombosis; whereas lower doses 
(around 250 mg/day, obtainable from fish consumption 
and low dose supplements such as cod liver oil (CLO)) 
have been observed to lower the risk of sudden death or 
CHD death in trials and observational studies, which may 
be due to the influence of n-3 PUFA on heart rate and 
arrhythmia.6–8 Reviews of trials on n-3 PUFA supplementa-
tion in relation to overall cardiovascular diseases (CVD),9 
or when separated into subgroups of stroke and coro-
nary diseases,10–12 have shown no overall benefit, partic-
ularly in the most recent trials. It has been suggested that 
background medication, inclusion of non-fatal events as 
outcome measures and increasing trends in n-3 PUFA/
fish consumption might underlie the null findings.13 14
Although there have been a number of studies on 
the association between n-3 PUFA intake and CHD, the 
evidence for a protective association between n-3 PUFA 
supplement intake and CHD remains inconclusive.15 
Consumption of n-3 PUFA supplements is tradition-
ally high in Northern European countries.16 A Swedish 
cohort observed no association for fish oil supplements 
and CVD mortality17; whereas a study based in Iceland 
observed a lower risk of CHD hospitalisation with high 
frequency of CLO consumption.18 Previous studies have 
relied on single baseline measures of supplement use and 
covariates,19 excluded fish oil supplement users because 
of minimal use in the studied cohort20 or lacked detailed 
data on supplement use and therefore imputed n-3 PUFA 
content21; moreover, trials have included participants at 
increased risk of CHD22–24 or included those who have 
already experienced a CHD event25–28; the effects of n-3 
PUFA supplementation in a general population are less 
well documented, and the first primary prevention trial 
is ongoing.29
The aim of this analysis was to use three repeated 
measures of supplement use to investigate the association 
between n-3 PUFA supplement intake and CHD mortality 
in a general population-based cohort.
MEthODs
An extended version of the methods has been included in 
online supplementary appendix I.
study design
Recruitment for the Norfolk-based European Prospective 
Investigation into Cancer and Nutrition (EPIC-Norfolk) 
started in 1993 and was completed in 1998.30 31 Thir-
ty-five general practices in the Norfolk area of East Anglia 
(UK) took part in the study; 77 630 registered patients 
were approached, 30 445 consented. Exposures have 
been reassessed over the course of the study; participants 
completed general Health and Lifestyle Questionnaires 
(HLQ) and attended three health examinations (HE) 
up to 2011 (figure 1, online supplementary appendix I). 
Data on health outcomes and mortality were collected 
passively. Ethical approval for the study was given by the 
Norwich District Health Authority Ethics Committee. 
Participants gave written informed consent.
Assessment of n-3 PuFA supplement use
Dietary supplements were defined according to the 
EU directive 2002/46/EC.32 Prescribed medication 
containing minerals and/or vitamins were not consid-
ered supplements. The sum of eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA) from supple-
ments were the main exposure, referred to as n-3 PUFA. 
We used data from three dietary supplement assessments 
(DSA), named DSA1, DSA2, DSA3. All covered a 1 week 
recall (online supplementary appendix I).
At each DSA, participants were grouped by the type of 
supplement they consumed:
 ► non-supplement users (NSU);
 ► non-n-3 PUFA supplement users (SU-n3): participants 
who consumed one or more supplements that did not 
contain n-3 PUFA;
 ► n-3 PUFA supplement users (SU+n3): participants 
who used n-3 PUFA supplements, either singly or in 
combination with other non-n-3 PUFA supplements.
Participants were also grouped into five categories iden-
tifying change in n-3 PUFA supplement use between two 
consecutive DSA (online supplementary appendix I and 
appendix II): ‘consistent NSU’, ‘was SU+n3’, ‘became 
SU+n3’, ‘consistent SU+n3’, ‘other SU’.
Average daily nutrient composition from supplements 
was calculated using the Vitamin and Mineral Supple-
ment system33 and added to the average daily food intake 
to obtain average total nutrient intake. Validation of these 
data with biomarkers were undertaken.5
Dietary covariates
The analyses adjust for potential dietary confounders 
measured at DSA1. Diet was assessed using a 7-day diet 
diary (7dDD) between 1993–1998.34 Data were entered 
by trained staff into DINER35 and checked and calcu-
lated by nutritionists using DINERMO.36 The underlying 
food composition tables were derived from McCance & 
Widdowson’s Composition of Foods and supplements.37 
Missing values for fatty acids were further completed 
using a recipe calculation system.38 39 The baseline 7dDD 
provided data on average daily energy intake (MJ/day), 
proportion of energy provided by macronutrients (%en), 
the sum of EPA and DHA intake (g/day) referred to as ‘n-3 
PUFA’ and consumption of the disaggregated amounts of 
fruit, vegetable, red meat, processed meat, white meat, 
and white and oily fish consumption (g/day).36
Assessment of other covariates
Social class was measured through occupational status 
(professional, managerial, skilled non-manual, skilled 
manual, semi-skilled, non-skilled). Highest education 
level achieved was divided in four categories (no quali-
fication, O-level, A-level, degree). Both variables were 
derived from HLQ1 (coinciding with DSA1) and are time-
fixed. The remaining covariates are time-dependent and 
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Figure 1 Number of participants included at each DSA time point studied, with different scenarios of exclusion due to missing 
data. *Social class, education, smoking status, physical activity, body mass index, marital status and alcohol consumption. 
The numbers in the orange and green boxes relate to the number of participants available when the two consecutive DSA 
were considered in the analysis. The grey area in the timeline represents unobserved time. For more information regarding data 
availability see supplementary appendix I. DSA, dietary supplement assessment; FU, follow-up; HE, health examination; HLQ, 
Health and Lifestyle Questionnaire.
refer to measures obtained at time points corresponding 
to the DSA (online supplementary appendix I). We iden-
tified participants at higher risk of CHD using responses 
to the questions, “Has the doctor ever told you that you 
have [myocardial infarction/diabetes/stroke]?”. Partici-
pants were classified as a never smoker, former smoker 
or current smoker. Alcohol consumption was classified as 
none, >0–14, >14–28, >28 units/week. Marital status was 
recategorised into married (married/living as married) 
or non-married (widowed, divorced, separated, single). 
Participants were classified as being active, moderately 
active, moderately inactive or inactive. Body mass index 
(BMI) (kg/m2) was calculated from height and weight 
measured by a trained nurse.
Participant selection, case ascertainment and outcomes 
studied
Participants were eligible for analyses if they provided 
data on supplement use at any of the three time points 
(DSA1, DSA2, DSA3) and attended the corresponding 
HE (figure 1); 4030 participants were not included at 
any time point studied. The participant’s National Health 
Service number (a unique national patient identifier) was 
linked to the data from the Office of National Statistics to 
obtain vital status and causes of death. A similar proce-
dure was followed for causes of hospital admissions regis-
tered by the East Norfolk Primary Healthcare Trust which 
records for its residents the admissions in England and 
Wales. The main endpoint studied was CHD mortality 
mentioned anywhere on the death certificate, identi-
fied with International Classification of Diseases (ICD) 
9 410–414 or ICD10 I20-I25. In sensitivity analyses, we 
investigated the use of different definitions for the CHD 
endpoint: (1) CHD mortality mentioned as underlying 
cause of death, (2) death due to acute myocardial infarc-
tion (ICD-codes 410 or I21) or (3) first recorded hospital-
isation due to CHD.
statistical analysis
A description of the cohort at DSA1, DSA2 and DSA3 
is given. To study potential changes in supplement user 
characteristics over time, a multinomial logistic regression 
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analysis was performed at each DSA with supplement use 
group as the outcome variables and the variables noted 
above as explanatory variables.
The main analyses used Cox regression, using the 
follow-up time scale. Individuals who died from causes 
other than the event of interest were censored at their 
date of death and individuals who did not die from any 
cause were censored at the end of follow-up (31 March 
2015).
First, we modelled associations between supplement 
use at DSA1 and CHD mortality, with adjustment for 
covariates measured at DSA1. A series of cumulative 
adjustment models were used: sex and age-adjusted esti-
mates (model 1); including smoking, BMI (kg/m2), phys-
ical activity, alcohol intake, social class, education and 
season in which the questionnaire was completed (model 
2); including self-reported myocardial infarction, stroke 
or diabetes (model 3); including energy intake (MJ/day) 
and disaggregated fruit (g/day), vegetable (g/day), red 
meat and processed meat (g/day), and white meat (g/
day) (model 4); including white fish (g/day) and oily fish 
(g/day) (model 5). Second, models 1–5 were fitted using 
quintiles of n-3 PUFA intake from food and supplements 
at DSA1 as the main exposure (online supplementary 
appendix III).
The above analyses were repeated using time-updated 
measures of supplement use and covariates using model 3. 
First, we performed separate analyses using DSA1, DSA2 
and DSA3 as the time origins. Second, we performed 
time-varying covariates modelling using the full length of 
follow-up as well as shorter length of follow-up time to 
acknowledge unobserved changes in individuals’ supple-
ment use over time. We equally applied the strategy 
described here using the change between supplement 
group categories between DSA.
We assessed interactions between supplement use and 
sex, age, self-reported illnesses, smoking and BMI using 
likelihood ratio tests.
At DSA1, participants with missing data on supplement 
use and covariables were excluded; at DSA2 and DSA3 
missing covariates from the last observation were carried 
forward (figure 1). Alternatively, multiple imputation was 
used to handle missing data in the Cox regression anal-
yses (supplementary appendix IV). The proportional 
hazards' assumption was assessed in the time-varying 
covariates model, by including interactions between time 
and each explanatory variable. Data were analysed using 
Stata V.14.
rEsults
Analyses were based on 22 035 participants who provided 
data at DSA1, 15 937 participants at DSA2 and 10 120 
participants at DSA3 (figure 1). Median (IQR) of 
follow-up time was 19 (17, 20) years. During this time, 
1562 participants (out of 22 035) died of CHD mentioned 
anywhere on the death certificate.
Description of included participants
Table 1 (and online supplementary appendix V) describes 
the study participants at each DSA. Included participants 
had a median age of 59, 65 and 69 years at DSA1, DSA2 
and DSA3, respectively, and consisted of 45%, 43% and 
44% men. We observed a lower smoking prevalence, 
fewer alcohol consumers and more physical inactivity as 
time progressed; however, there was still a large range in 
these behaviours. The proportion of NSU dropped from 
61% at DSA1 to 50% at DSA3, with 24%, 31% and 34% 
using n-3 PUFA containing supplements at the three DSA, 
respectively. The change in supplement use over time is 
depicted in online supplementary appendix II.
Multinomial logistic regression analysis assessed the 
relation of these characteristics to supplement use status, 
mutually adjusted, at DSA1, DSA2 and DSA3 (figure 2). 
Having a non-manual social class and a higher education 
level were associated with SU-n3; whereas older partici-
pants, non-smoking, alcohol consumption and fewer 
self-reported illnesses were asso
ciated with SU+n3. Associations between covariates and 
supplement use group were similar at the three DSA.
n-3 PuFA supplement users and hazard of chD mortality
There was no evidence that the CHD mortality of SU+n3 or 
SU-n3 differed from NSU when solely using baseline data 
(online supplementary appendix VI.). Table 2 shows 
results from the Cox proportional hazards analyses in 
which the time origin was reset at each DSA. No associa-
tion was observed between supplement use at DSA1 and 
CHD mortality for any amount of follow-up time. On 
the contrary, the HR of CHD mortality for SU+n3 rela-
tive to NSU at DSA2 and DSA3 was significantly below 1. 
With increasing follow-up time the HR attenuated, but 
remained statistically significant. We observed stronger 
associations, for all lengths of follow-up studied, between 
SU+n3 and CHD mortality in the later DSAs.
Using time-varying analysis, we observed a 26% lower 
hazard among SU+n3 compared with NSU (HR: 0.74, 
95% CI 0.66 to 0.84). Significant interactions between 
follow-up time and age, sex and self-reported myocardial 
infarction were observed; however, inclusion of these 
interaction terms resulted in negligible differences in the 
HR or 95% CI of the main exposure. Results presented 
are therefore without these interaction terms in the 
regression equation.
change in supplement use over time
Table 3 shows the results from analysis investigating 
changes in supplement use over time. There was no 
evidence to suggest that participants who were taking n-3 
PUFA supplements at an earlier point in time, but who 
stopped its use, had a different hazard of CHD mortality 
compared with consistent NSU (HRDSA1-DSA2 1.24, 95% CI 
0.94 to 1.64; HRDSA2-DSA3 1.20, 95% CI 0.79 to 1.81), there-
fore suggesting that there are no long term benefits of 
previous n-3 PUFA supplement use. Compared with 
consistent NSU, participants who reported n-3 PUFA 
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Table 1 Characteristics of the EPIC-Norfolk cohort at time of DSA1 (1993–1998), DSA2 (2002–2004) and DSA3 (2004–2011)
DSA1
n=22 035
DSA2
n=15 937
DSA3
n=10 120
CHD mortality events from DSA onwards (n) 1562 742 241
Total person years at risk (years) 383 444 173 239 63 535
Crude cumulative rate (per 1000 person years) 4.074 4.283 3.793
Supplement use
NSU 61 (13 444) 52 (8353) 50 (5029)
SU-n3 15 (3263) 17 (2665) 16 (1610)
SU+n3 24 (5328) 31 (4919) 34 (3481)
n-3 PUFA (g/day)*
From food only 0.12 (0.06–0.34) – –
From food and supplements combined 0.16 (0.07–0.40) – –
Among SU+n3 only 0.30 (0.17–0.72) – –
Sex
Men 45 (9890) 43 (6923) 44 (4418)
Women 55 (12 145) 57 (9014) 56 (5702)
Age (years) 59 (51–67) 65 (58–72) 69 (63–76)
BMI (kg/m2) 25.8 (23.7–28.3) 26.1 (24.0–28.7) 26.3 (24.0–29.0)
Smoking status
Current 11 (2395) 7 (1149) 5 (456)
Former 43 (9426) 50 (7982) 46 (4671)
Never 46 (10 214) 43 (6806) 49 (4993)
Social class
Professional 7 (1531) 8 (1203) 8 (852)
Managerial 37 (8048) 39 (6189) 40 (4047)
Skilled non-manual 17 (3715) 16 (2585) 16 (1658)
Skilled manual 23 (5055) 22 (3483) 21 (2131)
Semi-skilled 13 (2910) 13 (2007) 12 (1163)
Non-skilled 4 (776) 3 (470) 3 (269)
Marital status
Married 82 (18 127) 78 (12 394) 76 (7708)
Not married 18 (3908) 22 (3543) 24 (2412)
Education level
No qualification 36 (7999) 32 (5106) 28 (2851)
O-level 10 (2282) 11 (1757) 12 (1184)
A-level 41 (8955) 42 (6720) 44 (4427)
Degree 13 (2799) 15 (2354) 16 (1658)
Season
Spring 26 (5817) 23 (3645) 27 (2761)
Summer 25 (5473) 21 (3295) 30 (3008)
Autumn 26 (5661) 32 (5150) 25 (2513)
Winter 23 (5084) 24 (3847) 18 (1838)
Physical activity
Inactive 30 (6592) 36 (5809) 41 (4106)
Moderately inactive 29 (6389) 27 (4302) 28 (2792)
Moderately active 23 (5040) 20 (3151) 17 (1709)
Continued
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DSA1
n=22 035
DSA2
n=15 937
DSA3
n=10 120
Active 18 (4014) 17 (2675) 15 (1513)
Alcohol intake (HLQ)
None 13 (2930) 32 (5042) 33 (3312)
>0–14 units/week 72 (15 880) 52 (8336) 56 (5704)
>14–28 units/week 11 (2418) 12 (1950) 9 (869)
>28 units/week 4 (807) 4 (609) 2 (235)
Self-reported illness
Myocardial infarction 3 (704) 5 (717) 3 (330)
Stroke 1 (304) 2 (359) 2 (164)
Diabetes 2 (510) 5 (745) 3 (338)
Energy—7dDD (MJ/day)* 8.00 (6.71–9.56)
Protein (en%) 15.2 (13.6–16.9)
Fat (en%) 33.4 (29.8–36.8)
Saturated fat (en%) 12.7 (10.9–14.6)
Carbohydrates (en%) 47.6 (43.4–51.5)
Alcohol (en%) 2.0 (0–5.9)
Food intake—7dDD (g/day)*
Fruit 153 (82–242)
Vegetables 142 (102–190)
Red and processed meat 53 (32–76)
White meat 21 (6–37)
Oily fish 4 (0–19)
Consumers only (54%) 17 (10–30)
White fish 13 (0–23)
Consumers only (66%) 19 (13–29)
Total fish 23 (11–40)
Consumers only (84%) 28 (17–44)
Values are % (n) for categorical variables and median (IQR) for continuous variables.
*Data only available from DSA1, see also online supplementary appendix I; for more information on diet at DSA1, see online supplementary 
appendix V.
7dDD, 7-day diet diary; BMI, body mass index; CHD, coronary heart disease; DSA, dietary supplement assessment; EPIC, European 
Prospective Investigation into Cancer; HLQ, Health and Lifestyle Questionnaire; n-3 PUFA, omega-3 polyunsaturated fatty acids (sum of 
eicosapentaenoic acid and docosahexaenoic acid); NSU, non-supplement user; SU, supplement user.
Table 1 Continued 
supplement use at both time points, and participants who 
became a SU+n3 had a lower hazard of CHD mortality. 
This association was stronger in the time-varying covari-
ates analysis where we observed a HR of 0.69 (95%CI 
0.52 to 0.90) among starters of SU+n3 and a HR of 0.78 
(95%CI 0.63 to 0.98) among consistent SU+n3. Associa-
tions attenuated or became non-significant as follow-up 
time increased.
sensitivity analyses
Using different definitions for the endpoint (figure 3), 
we observed associations of similar strength for CHD as 
underlying cause of death (HR: 0.78, 95% CI 0.67 to 0.90) 
and for acute fatal myocardial infarction when compared 
with CHD mortality mentioned anywhere on the death 
certificate. No associations were observed for first event 
of hospitalisation due to CHD.
Associations between SU+n3 and CHD mortality 
were similar for men and women, for overweight and 
non-overweight participants, for participants with and 
without self-reported myocardial infarction or diabetes 
and among smokers and non-smokers (online supple-
mentary appendix IV). There was evidence of an interac-
tion between supplement use group and prevalent stroke 
(p=0.006); although the SU+n3 had similar HRs by preva-
lent stroke group, SU-n3 had not.
The primary analyses do not distinguish between 
SU+n3 who do or do not use other supplements. As an 
additional sensitivity analysis, we investigated this using 
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Figure 2 Characteristics of SU-n3 versus NSU and SU+n3 versus NSU measured at three time points (DSA1 [green], 
DSA2 [blue], DSA3 [red]) in the EPIC-Norfolk study. Three analyses from multinomial logistic regression at three time 
points: DSA1 (n=22 035), DSA2 (n=12 333), DSA3 (n=8126). The ORs are mutually adjusted for all variables shown. DSA, 
dietary supplement assessment; EPIC, European Prospective Investigation into Cancer; NSU, non-supplement user; PUFA, 
polyunsaturated fatty acids; SU+n3, n-3 PUFA supplement user; SU-n3, supplement user without n-3 PUFA.
a model with binary variables for n-3 PUFA supplement 
use and non n-3 PUFA supplement use and their inter-
action, finding that the association between n-3 PUFA 
supplement use and a reduced hazard persisted in those 
who used other supplements and those who did not. 
We found an estimated HR of 0.83 (95% CI 0.71 to 0.97) 
in those who only use an n-3 PUFA containing supple-
ment versus NSU, a HR of 0.91 (95% CI 0.78 to 1.06) 
for those who only use  non n-3 PUFA containing supple-
ments, and a HR of 0.66 (95% CI 0.56 to 0.79) versus NSU 
in those who used both, though there was no evidence 
that the association between n-3 PUFA containing supple-
ments and CHD was different in those taking no other 
supplements or in those taking other supplements and 
the HR in those taking n-3 PUFA supplements adjusted 
for other supplement use was 0.79 (95% CI 0.70 to 0.89).
DIscussIOn
statement of principal findings
We observed a protective association between n-3 PUFA 
supplement use and CHD mortality in this general popu-
lation where fish consumption was low and the mean age 
was approximately 60 years at baseline (DSA1). When 
data from three DSA were used, lower hazards of CHD 
mortality were observed for SU+n3 at all three DSA, 
which were strongest when the follow-up time was short; 
however, this analysis lacked statistical power. Using a 
time-varying covariates analysis, we observed a 26% lower 
hazard of CHD mortality among SU+n3 compared with 
NSU.
strengths and weaknesses of the study
A strength is the selection of participants at baseline from a 
general population as opposed to fish oil trials which have 
consisted of high-risk populations.11 Measures of covari-
ates and supplement use were available from three time 
points, which enabled mitigation of potential bias due to 
changes in supplement use over time. We could adjust for 
several variables representing health behaviours, as well 
as comorbidities, to account for potential confounding. 
The DSA had short recall periods of 1 week; however, we 
have previously shown that measures obtained from three 
instruments at baseline (DSA1), with recall times varying 
from 1 year to 1 week, had good agreement.40 Supple-
ment use in general is associated with health behaviours41 
and heterogeneity across supplement users exists, we 
therefore separated participants into SU+n3 and SU-n3 
and carefully assessed potential confounders at all DSA. 
A further strength was our use of multiple imputation 
to handle missing data (online supplementary appendix 
IV.).
The EPIC-Norfolk study has limitations. The baseline 
response rate was 39%; however, participants were found 
to be representative of the Health Survey for England 
population regarding anthropometry, blood pressure 
and blood lipids.30 There was loss to follow-up; however, 
outcomes were ascertained for those who no longer 
actively participated. Since the exact dates of supple-
ment use were not known as were the exact dates of 
self-reported myocardial infarction, stroke or diabetes, 
we are unable to say which happened first and therefore 
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Figure 3 Time-varying covariate analysis of the association between supplement use and hazard of CHD in the EPIC-Norfolk 
study (follow-up time from 1993 to 2015). (1) CHD mentioned anywhere on the death certificate (n=1640/24 330, as table 2). (2) 
CHD mentioned as underlying cause of death on death certificate (n=1084/24 330). (3) Acute myocardial infarction as underlying 
cause of death on death certificate (n=411/24 330). (4) Hospitalisation due to CHD (n=4087/24 217). The reshaped dataset for 
mortality analysis contains a larger number of participants (n=24 330) than available at DSA1 alone and therefore more events, 
since participants did not complete DSA1, but did complete DSA2 and/or DSA3; equally, some participants were excluded 
from DSA1 due to missing covariate data whereas these covariates were available at DSA2 and/or DSA3 and so the participant 
contributed follow-up time from DSA2 and/or DSA3 only. The reshaped dataset for hospitalisation analysis contains a smaller 
number of participants (n=24 216) than the mortality analysis, since participants who did not complete DSA1, but completed 
DSA2 or DSA3—however had a non-fatal event before DSA2 or DSA3, respectively—were excluded. Using adjustment model 
3: time-point specific age, smoking, BMI, alcohol consumption, physical activity, season of questionnaire completion, marital 
status and self-report of myocardial infarction, stroke or diabetes; as well as: sex, social class and education. NSU, non-
supplement users; SU-n3, non-N-3 PUFA supplement users; SU+n3, N-3 PUFA supplement users (mainly cod liver oil); MI, 
myocardial infarction.
the chronological ordering is unknown. Healthier indi-
viduals might have been more likely to continue active 
participation; however, we adjusted for a number of 
factors to mitigate potential bias arising due to this. The 
time intervals between DSA were relatively long, partic-
ularly between DSA1 and DSA2; therefore, misclassifi-
cation of the exposure is likely to have occurred. Data 
on fish consumption (and hence n-3 PUFA intake from 
food) from 7dDD could only be estimated at baseline 
(online supplementary appendix III). We considered 
the observed association between the SU+n3 and CHD 
mortality unlikely to be due to the nutrient/compound 
content of other non-n-3 PUFA supplements being used, 
and indeed in sensitivity analyses we found a significant 
association between n-3 PUFA supplement use and a 
reduced hazard in those using no other supplements. 
We also considered it unlikely that the observed associ-
ations could be due to the additional vitamins found in 
n-3 PUFA containing supplements, since these typically 
contain a 100% of the recommended nutrient intake and 
such doses have not been associated with cardiovascular 
mortality.42 43 Although we found a protective association 
between SU-n3 and a reduced hazard for CHD mortality 
in sensitivity analysis (0.87, 95% CI 0.76 to 0.98), the 
evidence for this was weak and we were unable to study 
the wide variety of individual nutrients/compounds in 
these supplements and we cannot rule out from these 
results that other supplements could be associated with 
CHD mortality. Identification of a specific nutrient and 
biological pathway, as well as the potential for a relative 
change in the type of supplement consumed among the 
SU-n3, requires additional analysis with emphasis on 
confounding by lifestyle and other factors, possibly partic-
ularly so if more than one non-n-3 PUFA supplement was 
consumed. Residual confounding due to dietary differ-
ences between SU+n3, SU-n3 and NSU, particularly 
those occurring over time, such as differences in fruit, 
vegetables and meat, also cannot be excluded. Lastly, the 
analyses required interpretation of many models, which 
will have increased the role of chance findings; however, 
the significant findings observed may be explained 
by biological mechanisms, the results were specific 
to SU+n3 and we observed significant associations of 
starting or continued use of n-3 PUFA supplements with 
a lower hazard for CHD mortality.
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Meaning of the study: possible explanations and implications 
for clinicians and policy-makers
The associations observed at the low dose of supplemental 
EPA and DHA in this cohort makes an antiarrhythmic 
function of n-3 PUFA, a likely biological pathway.6 7 In 
time-varying covariate analysis, it was observed that n-3 
PUFA supplement use was associated with 26% lower 
hazard of CHD mortality compared with non-supple-
ment use. A similar association has been estimated from 
trial and prospective cohort data6 which concluded that 
250–500 mg/day of n-3 PUFA lowered risk by 25% or 
more; a dose which corresponds to the intake from food 
and supplements of 300 mg/day observed in this cohort 
among SU+n3 (table 1). We have previously reported 
a non-significant association between plasma n-3 PUFA 
and CHD incidence in a sub-cohort of the EPIC-Norfolk 
study44; however, plasma concentrations were only avail-
able at baseline and are likely to have fluctuated over 
time, partly considering the variability in supplement 
use (online supplementary appendix II). The results 
between the studies are consistent when only relying 
on supplement data from DSA1 in the current anal-
ysis (online supplementary appendix VI). The VITAL 
cohort study found no significant association between 
increasing quartiles of n-3 PUFA intake from food and 
supplements and CHD (Ptrend=0.120), although a signif-
icant trend was observed for those participants free of 
baseline CHD (Ptrend=0.029). When including all DSA, 
effect modification for prevalent myocardial infarction 
was not observed in EPIC-Norfolk, which might be indic-
ative of the different motivations for CLO use in the UK 
versus fish oil supplement use in the USA.45 46 In Europe, 
the highest oily fish consumption is observed in Spain 
and Scandinavian countries, and is approximately 2–3 
fold higher than fish intake in the UK.47 A Norwegian 
cohort, where 30%–41% consumed two or more fish 
meals per week, observed no association between CLO 
consumption and CHD mortality.19 Fish could there-
fore have exceeded the threshold for an antiarrhythmic 
effect in this Norwegian cohort to which CLO could 
not add, but might supply a considerable contribu-
tion to n-3 PUFA intake in the UK. The AGES study in 
Iceland, where the majority of women consumed 2–4 
fish portion per week (85% lean fish), did observe a 
lower risk of hospitalisation due to CHD when n-3 PUFA 
from CLO was ≥5.9 g/week, whereas no association was 
observed with fish consumption.18 We did not observe 
any association with CHD hospitalisation; however, the 
n-3 PUFA dose in the AGES study was much higher and 
therefore efficacy might have been through atheroscle-
rotic pathways. Fish oil supplements cannot contain all 
the nutrients that would be obtained when consuming 
fish, or indeed the other meal components consumed 
with it (eg, vegetables) or the red meat replacement that 
took place,48 49 but n-3 PUFA supplements contain lower 
concentrations of contamination,50 and provide essen-
tial fatty acids without any coating and/or frying oils 
which might supply trans-fatty acids which are positively 
associated with CHD.11 This is consistent with findings 
that broiled or baked fish have been associated with a 
lower risk of CHD mortality, whereas fried fish has not.51 
Moreover, from DSA1, it is known that n-3 PUFA supple-
ments were consumed on a daily basis by approximately 
95% of the participants.40 Fish consumption has not 
been a daily dietary habit in the UK based on National 
Survey data in 2000/2001 and 2008/2009–2011/2012.4 52 
Incorporation of n-3 PUFA into plasma, platelets and red 
blood cells has been shown to be enhanced with a daily 
versus two times a week regimen of similar weekly supple-
ment doses.53
unanswered questions and future research
Food composition tables which include contaminants 
(online supplementary appendix III), nutrient composi-
tion from supplements and foods and which distinguish 
between fish preparation methods, could clarify any asso-
ciation between n-3 PUFA sources and CHD to further 
inform public health dietary guidelines. The results from 
the first primary prevention trial on n-3 PUFA supple-
ment use are to be expected.29
cOnclusIOn
Recent use of n-3 PUFA supplements was associated with 
a lower hazard of CHD mortality in a population-based 
cohort with low fish consumption. This association was 
specific to SU+n3 and independent of history of myocar-
dial infarction.
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